https://www.selleckchem.com/pr....oducts/gsk3368715.ht
8); in second-line treatment, 7.7 months (95% CI 2.8-11.; in third-line, 3.4 months (95% CI 2.3-not reached (NR)); and in fourth-line therapy or higher, 2.7 months (95% CI 1.2-NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line.Compositionally graded cylinders of Ti-Mn alloys were produced using the Laser Engineered Net Shaping (LENS™) technique, with Mn content varying from 0 to 12 wt.% along the cyl
Like
Comment
Share